Cipher Pharmaceuticals Inc. (CPHRF)
OTCMKTS
· Delayed Price · Currency is USD
9.99
-0.55 (-5.25%)
May 9, 2025, 2:31 PM EDT
Cipher Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 39.52 | 33.36 | 21.16 | 20.68 | 21.94 | 21.61 | Upgrade
|
| Revenue Growth (YoY) | 78.45% | 57.66% | 2.36% | -5.78% | 1.55% | -3.76% | Upgrade
|
| Cost of Revenue | 11.08 | 9.26 | 4.07 | 3.99 | 3.68 | 3.06 | Upgrade
|
| Gross Profit | 28.43 | 24.1 | 17.09 | 16.68 | 18.26 | 18.55 | Upgrade
|
| Selling, General & Admin | 15.72 | 12.24 | 5.43 | 4.55 | 5.11 | 6.26 | Upgrade
|
| Research & Development | 0.02 | - | 0.14 | 0.1 | 0.09 | 0.13 | Upgrade
|
| Operating Expenses | 21.29 | 16.26 | 6.79 | 5.63 | 5.2 | 6.39 | Upgrade
|
| Operating Income | 7.14 | 7.85 | 10.3 | 11.05 | 13.06 | 12.16 | Upgrade
|
| Interest Expense | -0.7 | - | - | - | -0.08 | -0.32 | Upgrade
|
| Interest & Investment Income | - | 0.33 | 1.87 | 0.46 | - | 0.03 | Upgrade
|
| Currency Exchange Gain (Loss) | -1.86 | -2.51 | 0.78 | -0.04 | 0.08 | 0.09 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | - | - | 0.01 | 0 | Upgrade
|
| EBT Excluding Unusual Items | 4.59 | 5.67 | 12.95 | 11.48 | 13.07 | 11.97 | Upgrade
|
| Merger & Restructuring Charges | -2.72 | -2.72 | -0.27 | - | - | -0.15 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | -0.76 | - | Upgrade
|
| Asset Writedown | - | - | - | - | - | -5.28 | Upgrade
|
| Legal Settlements | - | - | - | - | -1.25 | - | Upgrade
|
| Pretax Income | 1.87 | 2.96 | 12.68 | 11.48 | 11.06 | 6.54 | Upgrade
|
| Income Tax Expense | -7.37 | -8.59 | -7.7 | -15.16 | 3.3 | 2.15 | Upgrade
|
| Earnings From Continuing Operations | 9.25 | 11.55 | 20.38 | 26.64 | 7.76 | 4.39 | Upgrade
|
| Earnings From Discontinued Operations | - | - | - | - | - | 0.16 | Upgrade
|
| Net Income | 9.25 | 11.55 | 20.38 | 26.64 | 7.76 | 4.55 | Upgrade
|
| Net Income to Common | 9.25 | 11.55 | 20.38 | 26.64 | 7.76 | 4.55 | Upgrade
|
| Net Income Growth | -59.23% | -43.36% | -23.48% | 243.34% | 70.54% | 40.31% | Upgrade
|
| Shares Outstanding (Basic) | 25 | 25 | 25 | 25 | 27 | 27 | Upgrade
|
| Shares Outstanding (Diluted) | 26 | 25 | 25 | 26 | 27 | 27 | Upgrade
|
| Shares Change (YoY) | 1.75% | -0.79% | -1.46% | -3.84% | -1.96% | 1.52% | Upgrade
|
| EPS (Basic) | 0.36 | 0.47 | 0.82 | 1.05 | 0.29 | 0.17 | Upgrade
|
| EPS (Diluted) | 0.36 | 0.46 | 0.80 | 1.03 | 0.29 | 0.17 | Upgrade
|
| EPS Growth | -59.73% | -42.50% | -22.33% | 255.17% | 74.74% | 37.45% | Upgrade
|
| Free Cash Flow | -58.71 | -60.5 | 15.86 | 10.64 | 13.81 | 11.68 | Upgrade
|
| Free Cash Flow Per Share | -2.29 | -2.40 | 0.62 | 0.41 | 0.52 | 0.43 | Upgrade
|
| Gross Margin | 71.95% | 72.25% | 80.77% | 80.69% | 83.21% | 85.85% | Upgrade
|
| Operating Margin | 18.07% | 23.52% | 48.68% | 53.45% | 59.51% | 56.30% | Upgrade
|
| Profit Margin | 23.40% | 34.60% | 96.32% | 128.83% | 35.35% | 21.05% | Upgrade
|
| Free Cash Flow Margin | -148.57% | -181.33% | 74.92% | 51.48% | 62.95% | 54.06% | Upgrade
|
| EBITDA | 12.52 | 11.69 | 11.44 | 11.95 | 13.66 | 13.22 | Upgrade
|
| EBITDA Margin | 31.67% | 35.04% | 54.06% | 57.80% | 62.25% | 61.19% | Upgrade
|
| D&A For EBITDA | 5.38 | 3.84 | 1.14 | 0.9 | 0.6 | 1.06 | Upgrade
|
| EBIT | 7.14 | 7.85 | 10.3 | 11.05 | 13.06 | 12.16 | Upgrade
|
| EBIT Margin | 18.07% | 23.52% | 48.68% | 53.45% | 59.51% | 56.30% | Upgrade
|
| Effective Tax Rate | - | - | - | - | 29.85% | 32.90% | Upgrade
|
| Revenue as Reported | 39.52 | 33.36 | 21.16 | 20.68 | 21.94 | 21.61 | Upgrade
|
Updated Mar 18, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.